The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely to lose big time now that Donald Trump has been re-elected

Lisa Anne Michaels net worth and biography

Lisa Michaels Biography and Net Worth

EVP of Editas Medicine

Lisa Michaels is the Executive Vice President, Chief Medical Officer at Editas Medicine Inc.

How do I contact Lisa Anne Michaels?: The corporate mailing address for Dr. Michaels and other Editas Medicine executives is 11 Hurley Street, Cambridge MA, 02141. Editas Medicine can also be reached via phone at (617) 401-9000 and via email at [email protected]. Learn More on Lisa Anne Michaels' contact information.
Has Lisa Anne Michaels been buying or selling shares of Editas Medicine?: Lisa Anne Michaels has not been actively trading shares of Editas Medicine within the last three months. Most recently, Lisa Anne Michaels sold 1,568 shares of the business's stock in a transaction on Friday, November 12th. The shares were sold at an average price of $38.33, for a transaction totalling $60,101.44. Learn More on Lisa Anne Michaels' trading history.
Who are Editas Medicine's active insiders?: Editas Medicine's insider roster includes Katrine Bosley (CEO), Bruce Eaton (EVP), Lisa Michaels (EVP), James Mullen (CEO), and Michelle Robertson (CFO). Learn More on Editas Medicine's active insiders.
Are insiders buying or selling shares of Editas Medicine?: During the last year, Editas Medicine insiders bought shares 1 times. They purchased a total of 45,000 shares worth more than $253,800.00. During the last year, insiders at the sold shares 9 times. They sold a total of 131,534 shares worth more than $1,101,562.89. The most recent insider tranaction occured on September, 4th when EVP Baisong Mei sold 518 shares worth more than $1,771.56. Insiders at Editas Medicine own 1.9% of the company. Learn More about insider trades at Editas Medicine.
Information on this page was last updated on 9/4/2024.

Lisa Anne Michaels Insider Trading History at Editas Medicine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/12/2021	Sell	1,568	$38.33	$60,101.44

Lisa Anne Michaels Buying and Selling Activity at Editas Medicine

Editas Medicine Company Overview

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Today's Range

Now: $2.44

$2.33

$2.54

50 Day Range

MA: $3.20

$2.37

$3.91

2 Week Range

Now: $2.44

$2.30

$11.69

Volume

2,277,431 shs

Average Volume

2,170,941 shs

Market Capitalization

$201.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

From StockEarnings | Ad